Consortium

Partners

CHU de Nantes

Panticipant N°1 | Nantes | France

Role in the project

  • Work Package 1. Project management (lead): overall management of the project over 5 years
  • Work Package 2. rHu-IL-12 and IFN-γ for personalized immunotherapy trials in patients with HAP: coordination and sponsorship of the proposed trials
  • Work Package 3. Multi-omics characterization of patients at risk of HAP: samples management
  • Work Package 4 Systems biology integration – theranostic.
  • Work Package 5. Suitability, acceptability and adaptability of the interventions: economic evaluation
  • Work Package 6. Communication, Dissemination and Innovation Management

Prof. Roquilly is an intensivist leading innovative research on critical-illness associated immune suppression. He became over the last 10 years a specialist in clinical and immunological mechanisms of HAP with more than 90 publications and 4 patents and has notably demonstrated the corner role of IL12 in the susceptibility to HAP.

The Anaesthesia and Intensive Care Unit

Université de Nantes

Panticipant N°2 | Nantes | France

Role in the project

Department 1 – EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: in vitro stimulation of DCs of NK cells to measure the level of immunosuppression and functional ability to produce IL-12 and IFN-γ

Department 2 – UMR 1064 Centre de Recherche en Transplantation et Immunologie (CRTI)

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: Respiratory virome analysis

Department 3 – UMR INSERM 1246 – SPHERE

  • Work Package 5. Suitability, acceptability and adaptability of the interventions: Suitability, acceptability and adaptability assessment of the proposed interventions

The EA 3826 lab

 

ClÌnic Barcelona Hospital Universitari

Panticipant N°3 | Barcelona | Spain

Role in the project

  • Work Package 2. rHu-IL-12 and rHu-IFN-γ for personalized immunotherapy trials in patients with HAP: coordination of WP2, participation in the two proposed multi-center clinical trials and country lead for Spain

Prof. Antoni Torres, Dr. Laia Fernández-Barat & Dr. Miquel Ferrer

Prof. Torres is a world-renowned expert in the etiopathogenesis, histopathology, diagnosis and treatment of respiratory infections in patients in intensive care and particularly in those receiving mechanical ventilation. He is the first author of the International Guidelines for the management of HAP and VAP published in Eur Respir J (2017).

Dr, Fernández-Barat has significantly contributed to the creation of two inedited research lines in Spain: the study of biofilm in endotracheal tubes and the study of biofilm in bronchiectasis (BE) and chronic obstructive pulmonary disease (COPD).

Dr. Ferrer is a physician with expertise in severe acute respiratory failure, weaning from mechanical ventilation, intensive care unit-acquired pneumonia, community-acquired pneumonia, respiratory intensive and intermediate care.

University of Zurich

Panticipant N°4 | Zurich | Switzerland

Role in the project

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: overall coordination and supervision of WP3 activities and conducting mass-single cell cytometry analyses of circulating leukocytes

Prof. Burkhard Becher

Pr. Becher is a world-renowned inflammation researcher. His primary research focus is on cytokine networks in chronic inflammatory disorders. His team used preclinical models as well as patient material to understand communication networks of immune cells.

National and Kapodistrian University of Athens

Panticipant N°5 | Athens | Greece

Role in the project

  • Work Package 2. rHu-IL-12 and rHu-IFN-γ for personalized immunotherapy trials in patients with HAP: participation in the two proposed multi-center clinical trials and country lead for Greece
  • Work Package 6. Communication, Dissemination and Innovation Management: coordination of WP6

Prof. Apostolos Armaganidis and Dr. Despoina Koulenti

Prof. Armaganidis is Professor of Pulmonary and Intensive Care Medicine at National & Kapodistrian University of Athens, 2nd Critical Care Department with expertise in Sepsis, VAP,  Mechanical Ventilation, ARDS and Heart Lung Interaction

Dr Koulenti is a specialist physician in internal medicine & intensive care, Senior Consultant at the 2nd Critical Care Department of “Attikon” University General Hospital. Her research interest is infectious diseases/sepsis, especially in the critical care setting: severe community-acquired and nosocomial pneumonia, infections for multi-drug resistant (MDR) pathogens and antibiotic dosage optimisation.

University of Michigan

Panticipant N°6 | Ann Arbor, Michigan | United States of America

Role in the project

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: Respiratory bacterial microbiome analysis

Dr. Robert Dickson (left)

Robert Dickson is an international expert on the lung microbiome in health and critical illness. He has field-leading expertise in the techniques of microbiome sequencing, interpretation, and integration with clinical and immunologic metadata as they relate to lung disease.

Hospices Civils de Lyon

Panticipant N°7 | Lyon | France

Role in the project

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: Respiratory virome analysis

Dr. Laurence Josset

Dr. Laurence Josset is associate Professor (MCUPH) within the VirPath and Hospices Civils de Lyon (HCL) virology lab. She has a multidisciplinary background in Medical biology, Virology and Computational biology. Dr. Josset has extensive experience in NGS for viral sequencing and transcriptomic analysis of host response to viral infections.

Radboud umc

Panticipant N°8 | Nijmegen | Netherlands

Role in the project

  • Work Package 3. Multi-omics characterization of patients at risk of HAP: investigation of epigenetic regulation of the immune response after inflammation

Prof. Mihai G. Netea (right)

Prof. Mihai G. Netea, MD, PhD (male) is a specialist in Internal Medicine and Infectious Diseases with a strong focus on translational research in the field of innate immunity and pathophysiology of sepsis. He is an authority in the field of Innate Immunity, and he is in the top ten of most cited European authors in the field of Immunology (Lab Times 6/2013, Publication Analysis 2005-2011).

Neumedicines

Panticipant N°9 | Pasadena, California | United States of America

Role in the project

  • Work Package 2. rHu-IL-12 and IFN-? for personalized immunotherapy trials in patients with HAP: provision of rHu-IL-12, one of the two molecules investigated for prevention and treatment of HAP, follow-up and contribution to the scientific coordination of the two proposed randomized trials.

Dr. Christopher Lawrence

Dr. Christopher Lawrence received his doctorate in Immunology while researching at the Dept. of Immunology, Cambridge University, UK, and obtained a degree in Biochemistry, Newcastle University, UK.

He has 20 years of experience in the Pharmaceutical and Biotechnology industries, having successfully advanced 13 small molecules and biologics into clinical trials, optimizing their pharmacological, pharmacodynamic, and pharmacokinetic properties.

WeData

Panticipant N°10 | Nantes | France

Role in the project

  • Work Package 1. Project management: definition and implementation of a data management strategy
  • Work Package 4 Systems biology integration – theranostic: Development and validation of a clinico-biological score (HAP2 tool-box) for the classification of patients into low/high risk, and into responders/non-responders to treatment – integrating data from various sources and applying machine learning approaches to build a model predicting patient outcome.
  • Work Package 6. Communication, Dissemination and Innovation Management: working on reproducibility (centralize processing codes), data sharing and developing a decision-making tool to assist medical staff.

 

Mr. Olivier Breillacq, Director